Halting the Epidemic of Addiction and Loss Act of 2025
S. 2336
This bill requires that, when the Department of Health and Human Services (HHS) issues new regulations or guidance on grant programs addressing opioid use disorders, references to an opioid overdose reversal drug (e.g., naloxone) must broadly include any opioid overdose reversal drug approved by the Food and Drug Administration.
Read the full summary in the Pocket Congress app.